Australia markets open in 7 hours 20 minutes

Castle Biosciences, Inc. (CSTL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
20.79-0.48 (-2.26%)
As of 10:32AM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 555.23M
Enterprise value 302.68M
Trailing P/E 478.00
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)4.39
Price/book (mrq)1.35
Enterprise value/revenue 2.45
Enterprise value/EBITDA -5.57

Trading information

Stock price history

Beta (5Y monthly) 1.07
52-week change 3-48.56%
S&P500 52-week change 3-13.51%
52-week high 348.40
52-week low 315.58
50-day moving average 323.58
200-day moving average 328.15

Share statistics

Avg vol (3-month) 3200.79k
Avg vol (10-day) 3185.9k
Shares outstanding 526.35M
Implied shares outstanding 6N/A
Float 824.99M
% held by insiders 14.77%
% held by institutions 184.34%
Shares short (14 Nov 2022) 41.06M
Short ratio (14 Nov 2022) 44.3
Short % of float (14 Nov 2022) 44.84%
Short % of shares outstanding (14 Nov 2022) 44.04%
Shares short (prior month 13 Oct 2022) 41.3M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin -42.79%
Operating margin (ttm)-67.22%

Management effectiveness

Return on assets (ttm)-11.66%
Return on equity (ttm)-12.86%

Income statement

Revenue (ttm)123.74M
Revenue per share (ttm)4.80
Quarterly revenue growth (yoy)57.70%
Gross profit (ttm)78.26M
EBITDA -75.99M
Net income avi to common (ttm)-52.95M
Diluted EPS (ttm)-2.04
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)265.98M
Total cash per share (mrq)10.09
Total debt (mrq)13.56M
Total debt/equity (mrq)3.30
Current ratio (mrq)9.37
Book value per share (mrq)15.61

Cash flow statement

Operating cash flow (ttm)-38.44M
Levered free cash flow (ttm)-11.95M